Robert Ladner, Ph.D.CEO and Founder at CV6 Therapeutics
Bob brings more than 25 years of experience in the cancer research field, with a focus on biomarker discovery and drug development. In 2014, Bob became the CEO and Founder of CV6 Therapeutics, a biotechnology company dedicated to developing novel treatments to improve the effectiveness of currently approved, standard-of-care drugs in oncology and inflammatory diseases. In 2015, CV6 Therapeutics relocated from Southern California to Belfast, Northern Ireland to accelerate the translation of these novel drug development programs into the clinic.
Bob is currently a Reader in the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University Belfast and was formerly an Assistant Professor at the University of Southern California Norris Comprehensive Cancer Center where he initiated the development of novel therapeutics targeting uracil-DNA metabolism.
Bob holds a PhD and MSc from Rutgers University/The University of Medicine and Dentistry of New Jersey; and a BS degree from St. Joseph’s University in Philadelphia, Pennsylvania.